StreetInsider.com News Articles

Form 4 Century Therapeutics, For: Sep 09 Filed by: Truitt Joseph

Thu, 10 Sep 2026 17:49:00 -0400

si-local-file:///var/storage/secattach/20260910/27049588.html

Form 3 Century Therapeutics, For: Sep 09 Filed by: Truitt Joseph

Thu, 10 Sep 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260910/27049585.html

Century Therapeutics names Joseph Truitt to its board of directors

Wed, 09 Sep 2026 16:05:19 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Joseph Truitt to its board of directors, the biotechnology company announced.

Truitt currently serves as chief executive officer and board member of iECURE, Inc., a clinical-stage biotechnology company focused on genome-editing therapies. He also serves as chairman of the board of Larimar Therapeutics (NASDAQ: LRMR) and as a board member of Code Biotherapeutics.

Previously, Truitt was chief executive officer of BioSpecifics Technologies Corp. until its acquisition by Endo International plc in December 2020. Before that, he held several roles at Achillion Pharmaceuticals, including chief commercial officer, chief operating officer, and chief executive officer, prior to

Century Therapeutics names Joseph Truitt to its board of directors

Wed, 09 Sep 2026 16:05:19 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Joseph Truitt to its board of directors, the biotechnology company announced.

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors.

Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing genome-editing therapies for rare, life-threatening genetic diseases. He is Chairman of the Board of Larimar Therapeutics (NASDAQ: LRMR) and a member of the Board of Directors of Code

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Form 4 Century Therapeutics, For: Aug 14 Filed by: Pfeiffenberger Brent

Tue, 18 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260818/26944526.html

Form 4 Century Therapeutics, For: Aug 14 Filed by: Pfeiffenberger Brent

Tue, 18 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260818/26944526.html

Form 8-K Century Therapeutics, For: Aug 12

Wed, 12 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26909327.html

Form 8-K Century Therapeutics, For: Aug 12

Wed, 12 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26909327.html

Century Therapeutics, Inc. (IPSC) Misses Q2 EPS by 6c

Wed, 12 Aug 2026 08:03:57 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.17), $0.06 worse than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

Form 10-Q Century Therapeutics, For: Jun 30

Wed, 12 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26909239.html

Form 10-Q Century Therapeutics, For: Jun 30

Wed, 12 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26909239.html

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Wed, 12 Aug 2026 08:00:00 -0400

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026
CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D
Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D^® Clinical & Research Congress 2026 highlighting CNTY-813
Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion^™ 5.0 into the

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Wed, 12 Aug 2026 08:00:00 -0400

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026
CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D
Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D^® Clinical & Research Congress 2026 highlighting CNTY-813
Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion^™ 5.0 into the

Form 4 Century Therapeutics, For: Aug 03 Filed by: Carr Douglas

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874185.html

Form 4 Century Therapeutics, For: Aug 03 Filed by: Carr Douglas

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874185.html

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:26 -0400

Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific conferences scheduled for fall 2026, according to a company statement.

The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present in a session focused on stem cell-to-beta cell therapy.

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia,

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:26 -0400

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia,

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:26 -0400

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia,

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:26 -0400

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia,

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:18 -0400

Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific meetings scheduled for fall 2026, according to a company press release.

The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present during a session focused on stem cell-to-beta cell therapy.

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

Thu, 09 Jul 2026 08:00:00 -0400

PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:

62^nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy
Breakthrough T1D^® Clinical & Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania